Drug Trial Radar · NCT03008070
Phase 2b Study in NASH to Assess IVA337
Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
247
Actual
Start
Feb 7, 2017
Primary completion
Feb 20, 2020
Study completion Mar 16, 2020
Sponsor
- Lead sponsor
- Inventiva PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common. However, Treatment of NASH is a significant unmet clinical need. IVA337 (lanifibranor) is a next generation pan-PPAR (peroxisome proliferator-activated receptors) agonist addressing the pathophysiology of NASH : metabolic, inflammatory and fibrotic. The purpose of this research is to evaluate the efficacy and the safety of two doses of IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver steatosis and moderate to severe necroinflammation without cirrhosis.
Conditions
- Non-Alcoholic Steatohepatitis (NASH)
Interventions
IVA337Drug
1200mg
IVA337Drug
800mg
PlaceboDrug
Placebo to match
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F)Time frame: 24 weeks
Locations
85 sites in 16 countries. Site status is shown where the registry gives one.
North Alabama GI Research Center
Madison, Alabama
ACTRI
La Jolla, California
National Research Institute
Los Angeles, California
Palmetto Research, LLC
Hialeah, Florida
Florida Digestive Health Specialists, LLP
Lakewood Rch, Florida
Northeast GI Research Division
Concord, Massachusetts
Duke University Medical Center
Durham, North Carolina
Carolina's Center for Liver Disease/CHG
Huntersville, North Carolina
Jefferson University hospital
Philadelphia, Pennsylvania
Digestive Health Research, LLC
Hermitage, Tennessee
The Texas Liver Institute
San Antonio, Texas
Digestive Health Research, LLC
San Antonio, Texas
University of Virginia Health System
Charlottesville, Virginia
Virginia Commonwealth University
Richmond, Virginia
Flinders Medical Centre Department of Hepatology
Bedford Park, Australia
Monash Medical Centre
Clayton, Australia
Lyell McEwin Hospital & The University of Adelaide
Elizabeth Vale, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Fiona Stanley Hospital
Murdoch, Australia
Medical University Vienna
Vienna, Austria
Hopital Erasme
Brussels, Belgium
Clinique Universitaire Saint-luc
Brussels, Belgium
Antwerp University Hospital
Edegem, Belgium
Ziekenhuis Oost Limburg
Genk, Belgium
UZ Gent
Ghent, Belgium
"DCC Alexandrovska", EOOD
Sofia, Bulgaria
Acibadem City Clinic Tokuda Hospital
Sofia, Bulgaria
Acibadem City Clinic University Hospital EOOD
Sofia, Bulgaria
MHAT "Sveta Anna" Sofia
Sofia, Bulgaria
Military Medical Academy - MHAT
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski"
Sofia, Bulgaria
UMHAT "Tsaritsa Yoanna-ISUL"
Sofia, Bulgaria
University of Calgary
Calgary, Canada
The Bailey Health Clinic
Edmonton, Canada
CISSS de la Montérégie Centre
Greenfield Park, Canada
University of Western Ontario, London Health Sciences Centre
London, Canada
McGill University Health Centre (MUHC)
Montreal, Canada
Medpharmgene, Inc
Montreal, Canada
LAIR Centre
Vancouver, Canada
Researchsite S.R.O.
Pilsen, Czechia
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.